Compare Blackrock Inc (BLK) vs Teladoc Health Inc (TDOC) Price & Performance

BlackRock (BLK) trades at $1,031.56, down 0.44% on the day, with a bullish technical signal and strong analyst consensus. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 results anticipated. Revenue grew to $24.22 billion in 2025, though net income margin dipped to 22.93%. The company maintains robust profitability metrics, including a 24.4% net income margin and 11.95% ROE. Recent news highlights the launch of a new Nasdaq-100 ETF, IQQ, challenging Invesco's QQQ.

The outlook for BLK remains positive, driven by earnings momentum, strategic ETF expansion, and solid institutional support. Key risks include market volatility affecting asset management fees and competitive pressures in the ETF space. With 76% of analysts rating it a Buy and a consensus price target of $1,290, the stock presents a compelling opportunity for growth-oriented investors, though monitoring Q2 earnings and macroeconomic trends is essential.

TDOC trades at $9.65, up 3.99% with bullish technical signals but mixed fundamentals. Revenue remains stable around $2.5B, yet net losses persist with a -6.81% margin. Analyst consensus is cautious with 64% hold ratings, though recent partnerships like Walmart's Better Care show growth potential. Cash flow trends indicate significant net outflows, raising liquidity concerns despite a solid gross margin of 69.29%.

Outlook hinges on cost management and partnership execution; risks include sustained losses and high debt. The stock offers speculative upside if profitability improves, but investor patience is required amid competitive pressures and volatile sentiment. Current price near resistance at $10 suggests limited near-term upside without positive earnings surprises.